NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 1 filers reported holding NURIX THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,980 | -73.4% | 888 | -66.2% | 0.00% | -100.0% |
| Q2 2023 | $26,214 | +26378.8% | 2,624 | -76.4% | 0.00% | -66.7% |
| Q1 2023 | $99 | +1137.5% | 11,104 | +1488.6% | 0.00% | – |
| Q4 2022 | $8 | -100.0% | 699 | -93.0% | 0.00% | -100.0% |
| Q3 2022 | $131,000 | +129.8% | 10,035 | +121.6% | 0.00% | +100.0% |
| Q2 2022 | $57,000 | +90.0% | 4,529 | +113.0% | 0.00% | – |
| Q1 2022 | $30,000 | -77.9% | 2,126 | -54.6% | 0.00% | -100.0% |
| Q4 2021 | $136,000 | +65.9% | 4,685 | +71.3% | 0.00% | 0.0% |
| Q3 2021 | $82,000 | +6.5% | 2,735 | -6.0% | 0.00% | 0.0% |
| Q2 2021 | $77,000 | -31.2% | 2,910 | -19.1% | 0.00% | 0.0% |
| Q1 2021 | $112,000 | +30.2% | 3,596 | +38.2% | 0.00% | -33.3% |
| Q4 2020 | $86,000 | +38.7% | 2,602 | +45.5% | 0.00% | +200.0% |
| Q3 2020 | $62,000 | – | 1,788 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |